| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia
|
Jan, Max
|
|
|
4 |
3 |
p. 445-448
|
artikel
|
| 2 |
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
|
Goshua, George
|
|
|
4 |
3 |
p. 539-545
|
artikel
|
| 3 |
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia
|
Smith, Victoria M.
|
|
|
4 |
3 |
p. 525-529
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
4 |
3 |
p. i
|
artikel
|
| 5 |
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
|
Montalban-Bravo, Guillermo
|
|
|
4 |
3 |
p. 482-495
|
artikel
|
| 6 |
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
|
Tarver, Theodore C.
|
|
|
4 |
3 |
p. 514-524
|
artikel
|
| 7 |
Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis
|
Khatib, Rasha
|
|
|
4 |
3 |
p. 500-513
|
artikel
|
| 8 |
Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018;2(13):1608-1615.
|
|
|
|
4 |
3 |
p. 444
|
artikel
|
| 9 |
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
|
Jain, Nitin
|
|
|
4 |
3 |
p. 449-457
|
artikel
|
| 10 |
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia
|
Adnan Awad, Shady
|
|
|
4 |
3 |
p. 546-559
|
artikel
|
| 11 |
Organ responses with daratumumab therapy in previously treated AL amyloidosis
|
Chung, Alfred
|
|
|
4 |
3 |
p. 458-466
|
artikel
|
| 12 |
Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial
|
Knight, Jennifer M.
|
|
|
4 |
3 |
p. 467-476
|
artikel
|
| 13 |
Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx
|
Carden, Marcus A.
|
|
|
4 |
3 |
p. 477-481
|
artikel
|
| 14 |
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
|
Chan, Onyee
|
|
|
4 |
3 |
p. 530-538
|
artikel
|
| 15 |
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
|
Awasthi, Rakesh
|
|
|
4 |
3 |
p. 560-572
|
artikel
|
| 16 |
Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation
|
Metzgeroth, Georgia
|
|
|
4 |
3 |
p. 440-443
|
artikel
|
| 17 |
Understanding sickle cell disease: impact of surveillance and gaps in knowledge
|
Kaur, Mandip
|
|
|
4 |
3 |
p. 496-498
|
artikel
|
| 18 |
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
|
Fischer, Melissa A.
|
|
|
4 |
3 |
p. 586-598
|
artikel
|
| 19 |
Verbij FC, Sorvillo N, Kaijen PHP, et al. The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages. Blood Adv. 2017;1(5):293-305.
|
|
|
|
4 |
3 |
p. 499
|
artikel
|
| 20 |
WASP and Mst1 coregulate B-cell development and B-cell receptor signaling
|
Huang, Lu
|
|
|
4 |
3 |
p. 573-585
|
artikel
|
Tijdschrift beschrijving